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Introduction
Children with late-diagnosed phenylketonuria (PKU) suffer from severe behavioral 
problems except for intellectual disability. Hyperphenylalaninemia causes several 
behavioral disorders through suppression of dopamine and serotonin turnover that 
affects the prefrontal cortex of the brain (1). Common behavior problems in these 
children include autistic behaviors, aggression, hyperactivity, impulsive behavior, 
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Many patients with late-diagnosed phenylketonuria (PKU) suffer from severe 
behavior problems. This study compares the effects of buspirone and risperidone 
on reducing behavior disorders in these patients.
Materials & Methods
In this crossover clinical trial study, patients with severe behavior disorders after 
medical examination were randomly divided into two groups of two 8-week 
crossover treatments with risperidone or buspirone. Patient behavioral disorders 
before and after treatment by each drug was rated by parents on the Nisonger 
Child Behavior Rating Form (NCBRF), and after treatment by each drug, were 
assessed by a physician through clinical global impression (CGI).
Results
Thirteen patients were able to complete the therapy period with these two 
medications.
The most common psychiatric diagnoses were intellectual disability 
accompanied by pervasive developmental disorder NOS, and intellectual 
disability accompanied by autistic disorder. Risperidone was significantly 
effective in reducing the NCBRF subscales of hyperactivity disruptive/
stereotypic, and conduct problems. Treatment by buspirone only significantly 
decreased the severity of hyperactivity, but other behavior aspects showed no 
significant differences. Assessment of the severity of behavior disorder after 
treatment by risperidone and buspirone showed significant differences in 
reducing hyperactivity and masochistic/stereotype.
Conclusion
Although buspirone is effective in controlling hyperactivity in patients with 
PKU, it has no preference over risperidone. Therefore, it is recommended as an 
alternative to risperidone.
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in studies on patients with different underlying brain 
problems require a detailed interpretation of the results 
was not possible.
Materials& Methods
In this study, 42 patients aged 2–6 years with PKU (serum 
phenylalanine level > 6 mg/dl at the time of diagnosis, 
normal serum tyrosine) underwent initial assessment 
in the PKU specialized clinic of Besat Hospital of 
Hamadan, which is a provincial referral center for PKU 
patients. Then, cases with behavioral disorders (from 
the view of the parent and physical examination) were 
selected and referred to the Pediatric Psychiatry Clinic. 
A pediatric psychiatrist made the psychiatric diagnosis 
through a clinical interview based on DSM-IV-TR 
criteria for children <6 years and a semi-structured 
diagnostic interview (KSADS) for children > 6 years, 
and determined the need to receive drug treatment for 
each child according to the type of diagnosis, severity 
of symptoms, effect of behavior problems on children’s 
performance, and non-responsiveness to behavior 
interventions.
The Kiddie-schedule for affective disorders and 
schizophrenia-present and lifetime (KSADS) is a semi-
structured diagnostic interview that can be performed 
by a trained specialist for children aged 6–18 years. 
The interview consists of a screening interview, which 
evaluates symptoms of mood disorders, psychosis, 
anxiety disorders, elimination disorders (enuresis and 
encopresis), attention-deficit/hyperactivity disorder 
(ADHD), and oppositional defiant disorder, tick, and 
alcohol substance abuse. It also has five supplementary 
appendices in domains, including mood, anxiety, 
behavioral disorders, psychotic disorders, and 
substance abuse. The appendices will be completed if 
problematic domains are found during the screening 
interview. Hence, the interview provides the possibility 
of diagnosis of DSM-IV diagnoses in a wide range of 
psychiatric disorders. Interrater agreement in scoring 
screens and diagnoses was reported high (93–100%). 
Test-retest reliability kappa coefficient were in the 
excellent range for present and/or lifetime diagnoses 
of major depression, any bipolar, generalized anxiety, 
conduct, and oppositional defiant disorder (0.77–1.00) 
and in the good range concerning present diagnoses 
attention-deficit, and disruptive stereotypic movements 
(1,2). Lack of a pervasive PKU screening programs in 
Iran until one year ago have led to encountering a high 
number of late-diagnosed PKU patients with severe 
behavioral disorders. Parents of these children usually 
complain of uncontrollable and annoying behavior 
of their children, in addition to difficult feeding with 
phenylalanine-restricted diet, and they are often looking 
for a treatment to reduce behavioral problems. Current 
treatments available for reducing these types of disorders 
include antipsychotics and mood stabilizers, receptor 2α 
agonists, tricyclic antidepressants, and stimulant drugs 
such as Ritalin (3,4).
Several studies have shown the effectiveness of 
risperidone, atypical antipsychotics, and antagonists 
of dopamine D2 and serotonin 5-HT 2A receptors 
in controlling behavior problems (4), pervasive 
developmental disorders (5-10), disruptive behavior 
disorders (11-14), and intellectual disability (15-18). 
Hence, this drug has become the first-choice treatment 
for most behavioral disorders in patients with brain 
structural disorders. One of the major problems in the 
management of behavior disorders by antipsychotic 
drugs in these patients is the lack of clinical response 
and the occurrence of adverse effects in a portion of 
patients. Therefore, in these patients, alternative drugs 
are needed.
Some studies have reported the effectiveness of 
buspirone, a partial agonist of the 5-hydroxytryptamine-
1A (5-HT 1A) in the control of hostility and aggressive 
behaviors secondary to brain structural disorders (19). 
Another study has shown the effects of buspirone on the 
control of behavior disorders caused by brain trauma 
(20). In addition, some reports have indicated the 
efficacy of this drug in reducing anxiety and aggression 
in children with intellectual disabilities and autistic 
disorders (21,22).
The main purpose of this study compares the effects of 
risperidone and buspirone for treatment of behavioral 
disorders in children with PKU. If our findings are 
confirmed, buspirone can be introduced as an alternative 
drug to this group. The reason of selection of PKU 
patients for comparison of these two drugs were: firstly, 
the needs of these patients for an alternative drug and 
lack of similar studies on these patients; and secondly, 
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self-isolated/ritualistic, and overly sensitive (25-27).
Overall improvement was measured by the 7-point CGI 
after the end of the 8-week treatment period through 
asking question from parents and assessment of children 
by the therapist (28,29). This scale has been used to assess 
disease severity and overall improvement, and is scored 
on a 1–7 scale; the lower scores indicate the decrease 
of psychopathology and more therapeutic effects. The 
phenylalanine level of patients was measured at least 
one time during treatment with each drug. The exclusion 
criteria were an increase of behavioral disorders, adverse 
effects from the drugs, existence of a severe chronic 
diseases, and phenylalanine more than 10 mg/dl during 
the treatment period. The data obtained from NCBRF 
and CGI together with other PKU related data were 
collected from the dossiers of patients and were recorded 
on data collection forms. The data were analyzed using 
SPSS software (ver. 16).
Results
From 42 patients with PKU patients covered by the PKU 
Clinic of the Besat Hospital of Hamadan, 26 cases who 
had severe behavior problems were referred to a pediatric 
psychiatrist, from them, 22 cases were eligible to enter 
the project. Twenty eligible children were treated with 
risperidone and buspirone. Four cases withdrew from the 
project during the treatment and 3 cases became restless 
during the discontinuation of risperidone and starting 
buspirone. Therefore, risperidone was again started for 
them.
Finally, 13 patients were able to complete the 16-week 
period of treatment with the two drugs. The mean age of 
these patients was 7.71 ± 4.18. Eight of them were boys 
and five were girls. All 13 cases were diagnosed late and 
none of the patients had malignant PKU.
None of the patients had phenylalanine more than 10 mg/
dl during treatment, and the mean serum phenylalanine 
of the patients was not significantly different during 
treatment with the two drugs (p = 0.537).
The most common psychiatric diagnosis in 22 eligible 
patients was an intellectual disability accompanied 
by pervasive developmental disorders (not otherwise 
specified) (PDD NOS) and intellectual disability 
accompanied by autistic disorder (Table 1).
Assessment of the severity of behavioral disorder, 
of posttraumatic stress disorder and attention-deficit 
hyperactivity disorder (0.63–0.67). The existing data 
support the validity of KSADS diagnoses (23,24).
Intelligence status of the patient was assessed according 
to parental reports of childhood developmental history 
and patient current cognitive performance, and by the 
Wechsler Intelligence Test at ages over 5 years, and 
intellectual disability was being diagnosed according to 
DSM-IV criteria. After a written consent was obtained 
from the parents, the patients were randomly divided 
into 2 groups: the first group underwent treatment with a 
risperidone tablet in a dose range from 0.75 mg/d to 1.5 
mg/d, based on patient’s weight. Therefore, for children 
weighing less than 50 kg, risperidone was started at a dose 
of 0.25 mg/d and gradually increased to the final dose 
of 0.75 mg/d over a period of one week. Whereas, for 
children more than 50 kg, the starting dose of risperidone 
was 0.5 mg/d and the final dose was 1.5 mg/d. In the 
second group, for children less than 50 kg, buspirone 
was started at a dose of 2.5 mg/d, and was raised to 15 
mg/d over two weeks, and in children more than 50 kg, 
the initial dose was 5 mg/d and the final dose was 15 
mg/d. The treatment was continued for 8 weeks in both 
groups. After completing the 8 week treatment period, 
the dosage of the first drug was reduced and discontinued 
and then, patients in the first and second groups were 
given, respectively, buspirone and risperidone with the 
mentioned conditions. The second treatment period was 
continued for 8 weeks. Some patients were already under 
treatment with risperidone, the dose was only adjusted 
if needed, and they were placed in the buspirone group 
after 8 weeks.
Considering that all patients were in the intellectual 
disability range upon the initial assessment, they 
were evaluated in terms of changes in the severity of 
behavioral disorders in three stages of before treatment, 
after treatment with risperidone, and after treatment 
with buspirone by the NCBRF, which was completed by 
parents.
NCBRF has been designed specifically for the 
assessment of behavioral problems in children with 
intellectual disability. It consists of 10 items on social 
competence and 66 items on behavioral problems that 
comprise 6 subscales, including conduct problems, 
insecure/anxious, hyperactive, self-injury/stereotypic, 
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before and after treatment with risperidone by 
NCBRF showed significant decreases in the severity 
of subscales of hyperactivity (p=0.001), disruptive/
stereotypic (p=0.009), and conduct problems (p=0.043). 
Other aspects of behavior problems had no significant 
differences (Table 2).
In comparison of the effects of risperidone and 
buspirone, a decrease in the subscales of hyperactivity 
(p=0.024) and disruptive/stereotypic (p=0.042) in the 
risperidone group was significantly different from the 
buspirone group. Also, a decrease in the subscales of 
self-isolation (p=0.004) and insecure/anxious (p=0.031) 
in risperidone group was significantly different from the 
buspirone group; however, the comparison of before and 
after treatment was not significantly different (Table 2).
Concerning overall clinical efficacy according to CGI, 
risperidone (2.61 ± 0.50) was significantly more effective 
compared to buspirone (4.23 ± 1.48; p=0.006).
Discussion
The findings of our study reveal that risperidone is 
effective in the control of hyperactivity, disruptive/
stereotypic behaviors, and conduct problems in children 
with PKU .This finding is in accordance with other studies 
showing the effectiveness of risperidone in the decrease 
of hyperactivity, disruptive/stereotypic behaviors, and 
conduct problems in children with autistic disorder and 
intellectual disability(5-18, 30). Risperidone showed no 
significant differences in the control of other subscales 
of NCBRF (insecure/anxious, self-isolation, and overly 
sensitive), which may be justified by the type of disease 
in the studied group.
Buspirone was only effective in the control of 
hyperactivity; however, risperidone was significantly 
more effective. This finding is consistent with the 
results of Gualtieri and Stanislav et al studies (19,20). 
The notable point is the ineffectiveness of buspirone 
in reducing anxiety symptoms and risperidone is more 
effective in controlling anxiety symptoms. Considering 
that buspirone is an anti-anxiety drug, this finding seems 
contradictory. Nevertheless, given that the majority of 
children in this study had comorbidity with the range 
of pervasive developmental disorder; therefore, the 
symptoms reported by parents about their children’s 
anxiety in some items of NCBRF can result from social 
interaction disorder and its caused self-isolation, but is 
not due to social anxiety. Some studies have revealed 
that risperidone decreases hyperactivity, irritability, 
and stereotypic behaviors in autistic disorder and also 
increases verbal communication that can result in the 
reduction of parental’ reports of anxiety behavior.
In conclusion, this study shows that in spite of more 
advantages of risperidone than buspirone, in cases 
where the risperidone is not effective, buspirone could 
be administered as an alternative.
Studies with a larger sample size and on other groups 
with primary brain disorders are suggested.
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